Who are Panzyga, 10% Intravenous Solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PRIVIGEN (CSL Behring), Flebogamma 5% DIF, Gammaplex (5%), Asceniv™, IgPro, NewGam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/panzyga-10-intravenous-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Panzyga, 10% Intravenous Solution — Competitive Intelligence Brief

Panzyga, 10% Intravenous Solution (Panzyga, 10% Intravenous Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous Immunoglobulin (IVIG). Area: Immunology.

phase 3 Intravenous Immunoglobulin (IVIG) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Panzyga, 10% Intravenous Solution (Panzyga, 10% Intravenous Solution) — Octapharma. Panzyga is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and reduce inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Panzyga, 10% Intravenous Solution TARGET	Panzyga, 10% Intravenous Solution	Octapharma	phase 3	Intravenous Immunoglobulin (IVIG)
PRIVIGEN (CSL Behring)	PRIVIGEN (CSL Behring)	Hospices Civils de Lyon	marketed	Intravenous immunoglobulin (IVIg)	Fc receptors, complement system, pathogenic antigens and antibodies
Flebogamma 5% DIF	Flebogamma 5% DIF	Instituto Grifols, S.A.	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors, pathogenic antigens and antibodies
Gammaplex (5%)	Gammaplex (5%)	Bio Products Laboratory	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors and complement system (indirect mechanism via antibody delivery)
Asceniv™	Asceniv™	ADMA Biologics, Inc.	marketed	Intravenous immunoglobulin (IVIG)	Polyclonal immunoglobulins (IgG)
IgPro	IgPro	CSL Behring	marketed	Intravenous immunoglobulin (IVIG)	Multiple pathogenic antigens (polyvalent)
NewGam	NewGam	Octapharma	phase 3	Intravenous immunoglobulin (IVIG)	Multiple (polyspecific human immunoglobulins; Fc receptors and complement)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous Immunoglobulin (IVIG) class)

National Institute of Mental Health (NIMH) · 1 drug in this class
Octapharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Panzyga, 10% Intravenous Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/panzyga-10-intravenous-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab